trial · primary record
Pegzilarginase
Small-cell Lung Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2020-06-11 |
| Primary endpoint | Phase 1: Incidence of Treatment-realted Adverse Events as Assessed by CTCAE v4.0 |
| Registry ID | NCT03371979 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:33.222Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03371979
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.